These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19458008)

  • 1. Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.
    Goffinet C; Allespach I; Oberbremer L; Golden PL; Foster SA; Johns BA; Weatherhead JG; Novick SJ; Chiswell KE; Garvey EP; Keppler OT
    J Virol; 2009 Aug; 83(15):7706-17. PubMed ID: 19458008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
    Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
    J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
    Llibre JM; Martínez-Picado J
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():17-22. PubMed ID: 19572421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
    Bonczkowski P; De Scheerder MA; Malatinkova E; Borch A; Melkova Z; Koenig R; De Spiegelaere W; Vandekerckhove L
    Sci Rep; 2016 Dec; 6():38329. PubMed ID: 27910923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
    Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
    Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
    Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
    Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative PCR used to assess HIV-1 integration and 2-LTR circle formation in human macrophages, peripheral blood lymphocytes and a CD4+ cell line.
    Friedrich B; Li G; Dziuba N; Ferguson MR
    Virol J; 2010 Dec; 7():354. PubMed ID: 21129188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

  • 10. Different kinetics of viral replication and DNA integration in the main HIV-1 cellular reservoirs in the presence and absence of integrase inhibitors.
    Surdo M; Cortese MF; Orlandi C; Di Santo F; Aquaro S; Magnani M; Perno CF; Casabianca A; Ceccherini-Silberstein F
    Antiviral Res; 2018 Dec; 160():165-174. PubMed ID: 30420339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.
    Cooper A; García M; Petrovas C; Yamamoto T; Koup RA; Nabel GJ
    Nature; 2013 Jun; 498(7454):376-9. PubMed ID: 23739328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.
    Anker M; Corales RB
    Expert Opin Investig Drugs; 2008 Jan; 17(1):97-103. PubMed ID: 18095922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New tools to track HIV.
    Schacker T
    Nat Med; 2010 Apr; 16(4):373-4. PubMed ID: 20376041
    [No Abstract]   [Full Text] [Related]  

  • 14. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
    Kehlenbeck S; Betz U; Birkmann A; Fast B; Göller AH; Henninger K; Lowinger T; Marrero D; Paessens A; Paulsen D; Pevzner V; Schohe-Loop R; Tsujishita H; Welker R; Kreuter J; Rübsamen-Waigmann H; Dittmer F
    J Virol; 2006 Jul; 80(14):6883-94. PubMed ID: 16809294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
    Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
    Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
    Jones GS; Yu F; Zeynalzadegan A; Hesselgesser J; Chen X; Chen J; Jin H; Kim CU; Wright M; Geleziunas R; Tsiang M
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1194-203. PubMed ID: 19104010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.
    Sedaghat AR; Siliciano RF; Wilke CO
    Antivir Ther; 2009; 14(2):263-71. PubMed ID: 19430101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors.
    Gillim-Ross L; Cara A; Klotman ME
    J Gen Virol; 2005 Mar; 86(Pt 3):765-771. PubMed ID: 15722538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.